Increased LDL-C reduction with ezetimibe in ketogenic diet-induced hypercholesterolemia
Several case reports and a meta-analysis have documented significant increases in cholesterol levels among individuals following a ketogenic diet. However, the mechanistic drivers of this phenotype remain incompletely understood. Here, we describe a retrospective case series of 14 patients with ketogenic diet-induced hypercholesterolemia who experienced larger-than-expected LDL-C reductions after ezetimibe therapy. In a subset of participants with available genetic data, no biallelic sitosterolemia-associated variants were identified in the loci assessed. We hypothesize that chronically low insulin levels may alter hepatic cholesterol homeostasis through changes in ACAT2-mediated cholesterol esterification and in NPC1L1/ABCG5/G8-mediated cholesterol handling. The magnitude of LDL-C reduction achieved with ezetimibe in this cohort suggests that altered cholesterol absorption may contribute importantly to this phenotype. This hypothesis-generating framework offers a plausible mechanistic explanation and supports further prospective study of precision lipid management in ketogenic diet-induced hypercholesterolemia.
Authors
- Adrián Soto-Mota (ORCID: https://orcid.org/0000-0002-9173-7440)
- Tro Kalayjian (ORCID: https://orcid.org/0000-0001-5803-2804)
- Laura Buchanan (ORCID: https://orcid.org/0009-0009-3953-5858)
- Erin Saner
- Joshua Wageman
- Jorge Gonzalez
- Matthew Calkins
Institutions
- Amgen (United States) (US)
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
- Broward Health (US)
- ESS Bilbao (ES)
- Wake Forest University (US)
- Tecnológico de Monterrey (MX)
Publication Details
- Journal
- Lipids in Health and Disease
- Published
- 2026-08-24
- DOI
- https://doi.org/10.1186/s12944-026-03034-w
- Primary Topic
- Cholesterol and Lipid Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00